Novartis gives New York its layoff plans for Suffern; Poor-quality Indian generics go to Africa;

@FiercePharma: Now trending on FiercePharmaMarketing: First-to-market launch? Bonus--but double bonus if you're Big Pharma. Article | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. More | Follow @EricPFierce

@CarlyHFierce: This week in FiercePharmaMarketing: Takeda lets 900 reps fly at obesity; AZ + James Van Der Beek = FluMist sales? More | Follow @CarlyHFierce

> Novartis ($NVS) has mapped out for the state of New York how it will lay off its workers prior to a 2016 facility closure in Suffern. More

> Generic drugs that some Indian companies send to African countries are lower quality than the same medicines the companies sell at home and outside the African continent, a study has found. Report

> The U.K.'s drug cost watchdog is calling for a review of the way in which new drugs are adopted, evaluated and taken up by the Britain's National Health Service. More

> As it gears up to launch Duchenne muscular dystrophy treatment Translarna in the EU, PTC Therapeutics is adding execs to its global commercial team. Release

> Cipla has granted Salix Pharmaceuticals ($SLXP) exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family it controls. Release

Medical Device News

@FierceMedDev: Researchers develop the first blood test to diagnose adult depression. Story | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of polio vax application. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Drug delivery specialist Genisphere receives an additional $2M in funding. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Mainstay Medical CEO reveals company's path to market for its neuromodulation implant. More | Follow @EmilyWFierce

> Intrinsic raising $21M for implant to improve lumbar disc surgery. Story

> 23andMe customers must now opt in to find unknown close relatives via genetic test. More

> Mainstay Medical bucks M&A trend, sets own course for neuromodulation. News

Biotech News

@FierceBiotech: Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac. News | Follow @FierceBiotech

@JohnCFierce: Am I missing something? If the FDA eviscerates the low-T market, restricting use, doesn't that destroy the prospects of , Clarus, etc.? | Follow @JohnCFierce

@DamianFierce: $NVO's eye on a Seattle expansion could be balm to local biotech as Amgen heads for the door. Article | Follow @DamianFierce

@EmilyMFierce: ICYMI: Check out these 7 notable academic-pharma alliances of 2014. Feature | Follow @EmilyMFierce

> Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1. Story

> Merck's weekly diabetes drug stacks up to blockbuster Januvia in Phase III. Report

> Oral low-T drugs in the pipeline face a showdown with the FDA. More

Vaccines News

> Takeda reorg preps vaccines unit for emerging markets test. News

> 10 volunteers receive Glaxo Ebola vaccine with no adverse effects yet. Story

> Merck KGaA calls it quits on cancer vaccine--again. More

> Protein Sciences nabs stake in diabetes vax developer Diamyd. Story

> AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent. Article

Pharma Manufacturing News

> More FDA issues arise for Hospira in India. News

> Novartis says more cuts coming for New York Diovan plant. More

> FDA procedural delay on Rytary gives Impax breathing room. Report

> Baxter issues recall, this time because antibacterial gets mixed in wrong carton. Story

> Partner Sanofi wants to produce the insulin to be used in MannKind's Afrezza. Article

And Finally... Research shows zero-calorie sweeteners can raise your blood sugar. More (sub. req.)